Pinnacle Wealth Management Advisory Group LLC Has $276,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Pinnacle Wealth Management Advisory Group LLC lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 686 shares of the pharmaceutical company’s stock after selling 25 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Vertex Pharmaceuticals were worth $276,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of VRTX. Creative Planning lifted its holdings in Vertex Pharmaceuticals by 1.7% in the third quarter. Creative Planning now owns 80,467 shares of the pharmaceutical company’s stock valued at $37,424,000 after buying an additional 1,350 shares during the period. NBC Securities Inc. lifted its holdings in Vertex Pharmaceuticals by 34.5% in the third quarter. NBC Securities Inc. now owns 160 shares of the pharmaceutical company’s stock valued at $74,000 after buying an additional 41 shares during the period. Good Life Advisors LLC acquired a new position in Vertex Pharmaceuticals in the third quarter valued at $222,000. Stratos Wealth Advisors LLC lifted its holdings in Vertex Pharmaceuticals by 16.2% in the third quarter. Stratos Wealth Advisors LLC now owns 560 shares of the pharmaceutical company’s stock valued at $260,000 after buying an additional 78 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Vertex Pharmaceuticals by 87.9% in the third quarter. Blue Trust Inc. now owns 2,711 shares of the pharmaceutical company’s stock valued at $1,271,000 after buying an additional 1,268 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on VRTX shares. HC Wainwright restated a “buy” rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and upped their price objective for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Finally, Bank of America dropped their price objective on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a report on Thursday, December 19th. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $505.57.

Vertex Pharmaceuticals Stock Down 0.8 %

VRTX opened at $459.00 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The stock has a market cap of $118.21 billion, a price-to-earnings ratio of -230.65, a PEG ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company’s 50-day moving average price is $435.69 and its two-hundred day moving average price is $460.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.94 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.